$MDWD

MediWound Ltd. (MDWD): Financial results for Q2 2026

MediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it

Original reporting
Published Aug 13, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 6:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MDWD
Bearish
medium confidence
Mentioned
$MDWD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$MDWDBearishMed
01

Why it matters

The earnings release shows declining revenue and widening losses, but confirms full‑year guidance and new commercial agreements, suggesting mixed short‑term and long‑term implications.

02

Market read

The release provides fresh earnings data for a micro‑cap biotech, likely prompting short‑term price pressure but offering upside potential from pipeline milestones.

03

What to watch

Phase III EscharEx trial enrollment and BARDA contract may drive longer‑term upside despite near‑term revenue dip.

Relevance 7/10Novelty 8/10Timing: today at 8:30 a.m. ET

Background

MediWound Ltd., a Nasdaq‑listed biotech, filed its Q2 2026 earnings via Form 6‑K, highlighting trial updates and a BARDA partnership.

Company-level read

Ticker impact

$MDWDBearishMedium confidence
Context

Q2 2026 revenue was $3.1 million and full‑year guidance of $24‑26 million was reaffirmed.

Expected impact

Potential short‑term price decline as results fall short of prior quarter.

Evidence & confidence

Revenue down 45% YoY and net loss widening suggest pressure; guidance unchanged may limit upside.

Market effects

Biotech/health‑care sector may see modest pressure as small‑cap earnings miss expectations.

Limited to U.S. and Israeli markets where MediWound operates.

Low global impact; primarily affects niche investors in biotech.

Counterpoint

Guidance reaffirmation could support a bounce if investors focus on pipeline progress rather than short‑term miss.

Key entities

  • MediWound Ltd.

    Nasdaq‑listed biotech reporting Q2 2026 results.

  • Vericel

    Partnered with MediWound under a BARDA contract for NexoBrid.

Related articles

$HBANMed

Huntington Cut Its Outlook Right as the Fed Hiked. First Crack in Regional-Bank Margins?

Huntington Bancshares (HBAN) dropped 5.55% after lowering its 2027 EPS guidance to $1.75-$1.83 and 2026 net interest income growth to ~35%, citing rising deposit costs and loan pricing tightening. The Fed's rate hike exacerbated concerns about regional-bank margins, with peers like Fifth Third also seeing declines. Despite the selloff, Huntington's loan and deposit growth, along with fee income, provide some cushion. Analysts maintain an Overweight rating, with a price target of $21.

$005930.KSMedAI 8/10

Samsung Electronics Surges Over 3% in Early Trading as Memory Supercycle Expectations Build

Samsung Electronics shares rose 3.45% to 270,000 won ($190) in early trading, driven by expectations of increased memory semiconductor demand from AI infrastructure investments. KB Securities forecasts second-half operating profit of 221 trillion won ($159.4 billion), up 587% year-over-year, citing strong memory market growth and AI-driven demand. Analysts expect expanded shareholder returns and a potential share price recovery.

$LENHighAI 8/10

Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing

Lennar (NYSE: LEN) missed fiscal Q3 2026 earnings estimates, reporting adjusted EPS of $1.23 on revenue of $8.05 billion. Shares fell to a 52-week low near $76.07. Other homebuilders like D.R. Horton (NYSE: DHI) and PulteGroup (NYSE: PHM) also reported weak revenue growth and rising cancellation rates due to affordability pressures and high mortgage rates. Lennar's Q4 guidance was cautious, citing labor availability, resale competition, and market conditions as challenges.